Neal Ready
About
Neal Ready is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Neal Ready has authored 160 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 113 papers in Oncology, 87 papers in Pulmonary and Respiratory Medicine and 31 papers in Molecular Biology. Recurrent topics in Neal Ready's work include Lung Cancer Treatments and Mutations (71 papers), Lung Cancer Research Studies (51 papers) and Cancer Immunotherapy and Biomarkers (44 papers). Neal Ready is often cited by papers focused on Lung Cancer Treatments and Mutations (71 papers), Lung Cancer Research Studies (51 papers) and Cancer Immunotherapy and Biomarkers (44 papers). Neal Ready collaborates with scholars based in United States, Germany and Spain. Neal Ready's co-authors include Scott Antonia, Scott Gettinger, Matthew D. Hellmann, Hossein Borghaei, Laura Q.M. Chow, Rosalyn A. Juergens, Julie R. Brahmer, Naiyer A. Rizvi, Thomas A. D’Amico and Jonathan W. Goldman and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Neal Ready
157 papers receiving 5.6k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Neal Ready United States | 36 | 4.2k | 2.8k | 1.1k | 1.1k | 741 | 160 | 5.7k | ||
| Mary J. Fidler United States | 22 | 5.2k 1.2× | 3.7k 1.3× | 343 0.3× | 803 0.7× | 1.1k 1.5× | 115 | 6.4k | ||
| Jong‐Mu Sun South Korea | 44 | 4.8k 1.1× | 4.4k 1.6× | 486 0.4× | 1.5k 1.4× | 657 0.9× | 234 | 7.1k | ||
| Alexander Guminski Australia | 30 | 3.1k 0.7× | 1.2k 0.5× | 679 0.6× | 1.1k 1.1× | 860 1.2× | 114 | 4.2k | ||
| Aleksandra Szczęsna Poland | 23 | 4.4k 1.0× | 4.2k 1.5× | 463 0.4× | 1.2k 1.1× | 381 0.5× | 73 | 5.8k | ||
| Miklos Pless Switzerland | 34 | 3.2k 0.7× | 3.5k 1.3× | 251 0.2× | 959 0.9× | 426 0.6× | 140 | 5.3k | ||
| Rathi N. Pillai United States | 29 | 3.0k 0.7× | 1.5k 0.5× | 365 0.3× | 766 0.7× | 1.5k 2.0× | 87 | 4.4k | ||
| Y Ariyoshi Japan | 31 | 3.2k 0.8× | 2.8k 1.0× | 697 0.6× | 2.0k 1.8× | 204 0.3× | 127 | 5.5k | ||
| Erminia Massarelli United States | 32 | 3.2k 0.8× | 2.1k 0.8× | 198 0.2× | 1.2k 1.2× | 729 1.0× | 140 | 4.6k | ||
| Piotr Serwatowski Germany | 15 | 4.0k 1.0× | 3.5k 1.3× | 415 0.4× | 1.0k 1.0× | 760 1.0× | 28 | 5.3k | ||
| Kyuichi Kadota Japan | 40 | 1.9k 0.4× | 3.2k 1.2× | 306 0.3× | 1.1k 1.0× | 387 0.5× | 132 | 5.1k |
Countries citing papers authored by Neal Ready
Since
Specialization
Citations
This map shows the geographic impact of Neal Ready's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neal Ready with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neal Ready more than expected).
Fields of papers citing papers by Neal Ready
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Neal Ready. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neal Ready. The network helps show where Neal Ready may publish in the future.
Co-authorship network of co-authors of Neal Ready
This figure shows the co-authorship network connecting the top 25 collaborators of Neal Ready. A scholar is included among the top collaborators of Neal Ready based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neal Ready. Neal Ready is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Clarke, Jeffrey, George R. Simon, Hirva Mamdani, et al.. (2025). Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial. Nature Communications. 16(1). 93–93.
2.
Ready, Neal, et al.. (2025). 261TiP: A single arm phase II study of PCSK9 inhibitor, alirocumab, and PD-1 inhibitor, cemiplimab, in advanced immuno-refractory metastatic non-small cell lung cancer (TOP2201). Journal of Thoracic Oncology. 20(3). S162–S162.
3.
Wood, C. G., Jacob M. Kaufman, Jeffrey Crawford, et al.. (2025). Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis. Journal for ImmunoTherapy of Cancer. 13(2). e010395–e010395.
4.
Armstrong, Andrew J., William J. Geese, Yu-Han Hung, et al.. (2025). LRP1b Loss Predicts Sensitivity to Immunotherapy in Patients with NSCLC: An Analysis of the Phase III CheckMate-026 Randomized Trial. Clinical Cancer Research. 31(24). 5198–5210.
5.
Yu, Xiaoqing, Mengyu Xie, Joseph Johnson, et al.. (2023). Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity. Cancer Immunology Research. 11(4). 466–485.
6.
Morgensztern, Daniel, Benjamin Besse, Laurent Greillier, et al.. (2019). Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study. Clinical Cancer Research. 25(23). 6958–6966.
7.
Antonia, Scott, Scott Gettinger, Hossein Borghaei, et al.. (2018). P1.01-02 Long-Term Outcomes with First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up from CheckMate 012. Journal of Thoracic Oncology. 13(10). S458–S458.
8.
Yi, John S., Neal Ready, Patrick Healy, et al.. (2017). Immune Activation in Early-Stage Non–Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab. Clinical Cancer Research. 23(24). 7474–7482.
9.
Zandberg, Dan P., Alain P. Algazi, Antonio Jimeno, et al.. (2017). Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Preliminary results from a single-arm, phase 2 study. Annals of Oncology. 28. v372–v372.
10.
Paz‐Ares, Luis, Bradley W. Lash, István Albert, et al.. (2017). An open-label phase 3b/4 safety trial of flat-dose nivolumab plus ipilimumab in patients with advanced non-small cell lung cancer (NSCLC). Annals of Oncology. 28. ii48–ii49.
11.
Ryser, Marc D., Walter T. Lee, Neal Ready, Kevin Leder, & Jasmine Foo. (2016). Quantifying the Dynamics of Field Cancerization in Tobacco-Related Head and Neck Cancer: A Multiscale Modeling Approach. Cancer Research. 76(24). 7078–7088.
12.
Socinski, Mark A., Ben Creelan, Leora Horn, et al.. (2016). NSCLC, metastatic CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC. Annals of Oncology. 27. vi577–vi577.
13.
Bauer, Todd M., David R. Spigel, Neal Ready, et al.. (2016). ORAL02.01: Safety and Efficacy of Single-Agent Rovalpituzumab Tesirine, a DLL3-Targeted ADC, in Recurrent or Refractory SCLC. Journal of Thoracic Oncology. 11(11). S252–S253.
14.
Chu, Quincy S., Ben Markman, Natasha B. Leighl, et al.. (2016). A phase 1/2 trial of a monoclonal antibody targeting fucosyl GM1 in relapsed/refractory small cell lung cancer (SCLC): Safety and preliminary efficacy. Annals of Oncology. 27. vi494–vi494.
15.
Boyer, Matthew J., Lin Gu, Xiaofei Wang, et al.. (2016). Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer. Lung Cancer. 98. 76–78.
16.
Ready, Neal, Nina Karaseva, С. В. Орлов, et al.. (2011). Double-Blind, Placebo-Controlled, Randomized Phase 2 Study of the Proapoptotic Agent AT-101 Plus Docetaxel, in Second-Line Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 6(4). 781–785.
17.
Birnbaum, Ariel E., Howard Safran, Thomas A. DiPetrillo, et al.. (2011). Pathologic Response After Neoadjuvant Carboplatin and Weekly Paclitaxel for Early-Stage Lung Cancer: A Brown University Oncology Group Phase II Study. Journal of Thoracic Oncology. 6(8). 1432–1434.
18.
Pepek, Joseph M., Junzo Chino, Lawrence B. Marks, et al.. (2011). How Well Does the New Lung Cancer Staging System Predict for Local/Regional Recurrence After Surgery?: A Comparison of the TNM 6 and 7 Systems. Journal of Thoracic Oncology. 6(4). 757–761.
19.
Grieco, Charlotte, Caroline J. Simon, William W. Mayo-Smith, et al.. (2006). Percutaneous Image-guided Thermal Ablation and Radiation Therapy: Outcomes of Combined Treatment for 41 Patients with Inoperable Stage I/II Non–Small-Cell Lung Cancer. Journal of Vascular and Interventional Radiology. 17(7). 1117–1124.
20.
Birnbaum, Ariel E. & Neal Ready. (2005). Gefitinib therapy for non-small cell lung cancer. Current Treatment Options in Oncology. 6(1). 75–81.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Mary J. Fidler Breakdown of academic impact, for papers by Jong‐Mu Sun Breakdown of academic impact, for papers by Alexander Guminski Breakdown of academic impact, for papers by Aleksandra Szczęsna Breakdown of academic impact, for papers by Miklos Pless Breakdown of academic impact, for papers by Rathi N. Pillai Breakdown of academic impact, for papers by Y Ariyoshi Breakdown of academic impact, for papers by Erminia Massarelli Breakdown of academic impact, for papers by Piotr Serwatowski Breakdown of academic impact, for papers by Kyuichi Kadota